Amphastar Pharmaceuticals, Inc. earnings per share and revenue
On Nov 06, 2025, AMPH reported earnings of 0.93 USD per share (EPS) for Q3 25, beating the estimate of 0.84 USD, resulting in a 10.58% surprise. Revenue reached 191.84 million, compared to an expected 188.42 million, with a 1.81% difference. The market reacted with a -0.83% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analysts forecast an EPS of 0.94 USD, with revenue projected to reach 194.29 million USD, implying an increase of 1.08% EPS, and increase of 1.28% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Teva Pharmaceutical Industries Limited - ADR
Report Date
Jan 28, 2026 For Q4 25
Estimate
$0.69
Actual
$0.96
Surprise
+38.55%
Dr. Reddy's Laboratories Limited - ADR
Report Date
Jan 21, 2026 For Q3 26
Estimate
$13.86
Actual
$14.65
Surprise
+5.66%
FAQ
What were Amphastar Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Amphastar Pharmaceuticals, Inc. reported EPS of $0.93, beating estimates by 10.58%, and revenue of $191.84M, 1.81% above expectations.
How did the market react to Amphastar Pharmaceuticals, Inc.'s Q3 2025 earnings?
The stock price moved down -0.83%, changed from $24.23 before the earnings release to $24.03 the day after.
When is Amphastar Pharmaceuticals, Inc. expected to report next?
The next earning report is scheduled for Feb 25, 2026.
What are the forecasts for Amphastar Pharmaceuticals, Inc.'s next earnings report?
Based on 9
analysts, Amphastar Pharmaceuticals, Inc. is expected to report EPS of $0.94 and revenue of $194.29M for Q4 2025.